Copyright Reports & Markets. All rights reserved.

Dynamics in Post-pandemic Global Microbiome Drugs Industry: Supply and Demand, Markets and Prices 2021-2027

Request for Sample of this report
Buy now

Table of Contents

    1 Product Introduction and Overview

    • 1.1 Product Definition
    • 1.2 Product Specification
    • 1.3 Global Market Overview
      • 1.3.1 Global Microbiome Drugs Market Status and Forecast (2016-2027)
      • 1.3.2 Global Microbiome Drugs Sales Value CAGR by Region
    • 1.4 Market Drivers, Inhibitors
      • 1.4.1 Market Drivers
      • 1.4.2 Market Inhibitors
      • 1.4.3 COVID-19 Impact Analysis

    2 Global Microbiome Drugs Supply by Company

    • 2.1 Global Microbiome Drugs Sales Volume by Company
    • 2.2 Global Microbiome Drugs Sales Value by Company
    • 2.3 Global Microbiome Drugs Price by Company
    • 2.4 Microbiome Drugs Production Location and Sales Area of Main Manufacturers
    • 2.5 Trend of Concentration Rate

    3 Global and Regional Microbiome Drugs Market Status by Category

    • 3.1 Microbiome Drugs Category Introduction
      • 3.1.1 Probiotics
      • 3.1.2 Prebiotics
      • 3.1.3 Small Molecules
      • 3.1.4 Biological Drugs
      • 3.1.5 Others
    • 3.2 Global Microbiome Drugs Market by Category
      • 3.2.1 Global Microbiome Drugs Sales Volume by Category (2016-2021)
      • 3.2.2 Global Microbiome Drugs Sales Value by Category (2016-2021)
      • 3.2.3 Global Microbiome Drugs Price by Category (2016-2021)
    • 3.3 North America: by Category
    • 3.4 Europe: by Category
    • 3.5 Asia Pacific: by Category
    • 3.6 Central & South America: by Category
    • 3.7 Middle East & Africa: by Category

    4 Global and Regional Microbiome Drugs Market Status by End User/Segment

    • 4.1 Microbiome Drugs Segment by End User/Segment
      • 4.1.1 Hospital Pharmacies
      • 4.1.2 Retail Pharmacies
      • 4.1.3 Online Pharmacies
      • 4.1.4 Others
    • 4.2 Global Microbiome Drugs Market by End User/Segment
      • 4.2.1 Global Microbiome Drugs Sales Volume by End User/Segment (2016-2021)
      • 4.2.2 Global Microbiome Drugs Sales Value by End User/Segment (2016-2021)
      • 4.2.3 Global Microbiome Drugs Price by End User/Segment (2016-2021)
    • 4.3 North America: by End User/Segment
    • 4.4 Europe: by End User/Segment
    • 4.5 Asia Pacific: by End User/Segment
    • 4.6 Central & South America: by End User/Segment
    • 4.7 Middle East & Africa: by End User/Segment

    5 Global Microbiome Drugs Market Status by Region

    • 5.1 Global Microbiome Drugs Market by Region
      • 5.1.1 Global Microbiome Drugs Sales Volume by Region
      • 5.1.2 Global Microbiome Drugs Sales Value by Region
    • 5.2 North America Microbiome Drugs Market Status
    • 5.3 Europe Microbiome Drugs Market Status
    • 5.4 Asia Pacific Microbiome Drugs Market Status
    • 5.5 Central & South America Microbiome Drugs Market Status
    • 5.6 Middle East & Africa Microbiome Drugs Market Status

    6 North America Microbiome Drugs Market Status

    • 6.1 North America Microbiome Drugs Market by Country
      • 6.1.1 North America Microbiome Drugs Sales Volume by Country (2016-2021)
      • 6.1.2 North America Microbiome Drugs Sales Value by Country (2016-2021)
    • 6.2 United States
    • 6.3 Canada
    • 6.4 Mexico

    7 Europe Microbiome Drugs Market Status

    • 7.1 Europe Microbiome Drugs Market by Country
      • 7.1.1 Europe Microbiome Drugs Sales Volume by Country (2016-2021)
      • 7.1.2 Europe Microbiome Drugs Sales Value by Country (2016-2021)
    • 7.2 Germany
    • 7.3 France
    • 7.4 UK
    • 7.5 Italy
    • 7.6 Russia
    • 7.7 Spain

    8 Asia Pacific Microbiome Drugs Market Status

    • 8.1 Asia Pacific Microbiome Drugs Market by Country
      • 8.1.1 Asia Pacific Microbiome Drugs Sales Volume by Country (2016-2021)
      • 8.1.2 Asia Pacific Microbiome Drugs Sales Value by Country (2016-2021)
    • 8.2 China
    • 8.3 Japan
    • 8.4 Korea
    • 8.5 Southeast Asia
    • 8.6 India
    • 8.7 Australasia

    9 Central & South America Microbiome Drugs Market Status

    • 9.1 Central & South America Microbiome Drugs Market by Country
      • 9.1.1 Central & South America Microbiome Drugs Sales Volume by Country (2016-2021)
      • 9.1.2 Central & South America Microbiome Drugs Sales Value by Country (2016-2021)
    • 9.2 Brazil
    • 9.3 Argentina
    • 9.4 Colombia

    10 Middle East & Africa Microbiome Drugs Market Status

    • 10.1 Middle East & Africa Microbiome Drugs Market by Country
      • 10.1.1 Middle East & Africa Microbiome Drugs Sales Volume by Country (2016-2021)
      • 10.1.2 Middle East & Africa Microbiome Drugs Sales Value by Country (2016-2021)
    • 10.2 Iran
    • 10.3 Israel
    • 10.4 Turkey
    • 10.5 South Africa
    • 10.8 Saudi Arabia

    11 Supply Chain and Manufacturing Cost Analysis

    • 11.1 Supply Chain Analysis
    • 11.2 Production Process Chart Analysis
    • 11.3 Raw Materials and Key Suppliers Analysis
      • 11.3.1 Raw Materials Introduction
      • 11.3.2 Raw Materials Key Suppliers List
    • 11.4 Microbiome Drugs Manufacturing Cost Analysis
    • 11.5 Microbiome Drugs Sales Channel and Distributors Analysis
      • 11.5.1 Microbiome Drugs Sales Channel
      • 11.5.2 Microbiome Drugs Distributors
    • 11.6 Microbiome Drugs Downstream Major Buyers

    12 Global Microbiome Drugs Market Forecast by Category and by End User/Segment

    • 12.1 Global Microbiome Drugs Sales Volume and Sales Value Forecast (2022-2027)
    • 12.2 Global Microbiome Drugs Forecast by Category
      • 12.2.1 Global Microbiome Drugs Sales Volume Forecast by Category
      • 12.2.2 Global Microbiome Drugs Sales Value Forecast by Category
      • 12.2.3 Global Microbiome Drugs Price Forecast by Category
    • 12.3 Global Microbiome Drugs Forecast by End User/Segment
      • 12.3.1 Global Microbiome Drugs Sales Volume Forecast by End User/Segment
      • 12.3.2 Global Microbiome Drugs Sales Value Forecast by End User/Segment
      • 12.3.3 Global Microbiome Drugs Price Forecast by End User/Segment

    13 Global Microbiome Drugs Market Forecast by Region/Country

    • 13.1 Global Microbiome Drugs Market Forecast by Region (2022-2027)
      • 13.1.1 Global Microbiome Drugs Sales Volume Forecast by Region (2022-2027)
      • 13.1.2 Global Microbiome Drugs Sales Value Forecast by Region (2022-2027)
    • 13.2 North America Market Forecast
    • 13.3 Europe Market Forecast
    • 13.4 Asia Pacific Market Forecast
    • 13.5 Central & South America Market Forecast
    • 13.6 Middle East & Africa Market Forecast

    14 Key Participants Company Information

    • 14.1 Seres Therapeutics
      • 14.1.1 Company Information
      • 14.1.2 Microbiome Drugs Product Introduction
      • 14.1.3 Seres Therapeutics Microbiome Drugs Sales Volume, Price, Sales Value and Gross Margin (2019-2021)
      • 14.1.4 SWOT Analysis
    • 14.2 Second Genome
      • 14.2.1 Company Information
      • 14.2.2 Microbiome Drugs Product Introduction
      • 14.2.3 Second Genome Microbiome Drugs Sales Volume, Price, Sales Value and Gross Margin (2019-2021)
      • 14.2.4 SWOT Analysis
    • 14.3 Ritter Pharmaceuticals
      • 14.3.1 Company Information
      • 14.3.2 Microbiome Drugs Product Introduction
      • 14.3.3 Ritter Pharmaceuticals Microbiome Drugs Sales Volume, Price, Sales Value and Gross Margin (2019-2021)
      • 14.3.4 SWOT Analysis
    • 14.4 Rebiotix
      • 14.4.1 Company Information
      • 14.4.2 Microbiome Drugs Product Introduction
      • 14.4.3 Rebiotix Microbiome Drugs Sales Volume, Price, Sales Value and Gross Margin (2019-2021)
      • 14.4.4 SWOT Analysis
    • 14.5 Pfizer
      • 14.5.1 Company Information
      • 14.5.2 Microbiome Drugs Product Introduction
      • 14.5.3 Pfizer Microbiome Drugs Sales Volume, Price, Sales Value and Gross Margin (2019-2021)
      • 14.5.4 SWOT Analysis
    • 14.6 OpenBiome
      • 14.6.1 Company Information
      • 14.6.2 Microbiome Drugs Product Introduction
      • 14.6.3 OpenBiome Microbiome Drugs Sales Volume, Price, Sales Value and Gross Margin (2019-2021)
      • 14.6.4 SWOT Analysis
    • 14.7 MicroBiome Therapeutics
      • 14.7.1 Company Information
      • 14.7.2 Microbiome Drugs Product Introduction
      • 14.7.3 MicroBiome Therapeutics Microbiome Drugs Sales Volume, Price, Sales Value and Gross Margin (2019-2021)
      • 14.7.4 SWOT Analysis
    • 14.8 MaaT Pharma
      • 14.8.1 Company Information
      • 14.8.2 Microbiome Drugs Product Introduction
      • 14.8.3 MaaT Pharma Microbiome Drugs Sales Volume, Price, Sales Value and Gross Margin (2019-2021)
      • 14.8.4 SWOT Analysis
    • 14.9 Enterome Bioscience
      • 14.9.1 Company Information
      • 14.9.2 Microbiome Drugs Product Introduction
      • 14.9.3 Enterome Bioscience Microbiome Drugs Sales Volume, Price, Sales Value and Gross Margin (2019-2021)
      • 14.9.4 SWOT Analysis

    15 Conclusion

      16 Methodology

      Covid-19 has impacted the supply and demand status for many industries along the supply chain. In this report a comprehensive analysis of current global Microbiome Drugs market in terms of demand and supply environment is provided, as well as price trend currently and in the next few years. Global leading players are profiled with their revenue, market share, profit margin, major product portfolio and SWOT analysis. From industry perspective this report analyses supply chain, including process chart introduction, upstream key raw material and cost analysis, distributor and downstream buyer analysis. This report also includes global and regional market size and forecast, major product development trend and typical downstream segment scenario, under the context of market drivers and inhibitors analysis. According to this survey, the global Microbiome Drugs market is estimated to have reached $ xx million in 2020, and projected to grow at a CAGR of xx% to $ xx million in 2027.

      Segmented by Category
      Probiotics
      Prebiotics
      Small Molecules
      Biological Drugs
      Others

      Segmented by End User/Segment
      Hospital Pharmacies
      Retail Pharmacies
      Online Pharmacies
      Others

      Segmented by Country
      North America
      United States
      Canada
      Mexico
      Europe
      Germany
      France
      UK
      Italy
      Russia
      Spain
      Asia Pacific
      China
      Japan
      Korea
      Southeast Asia
      India
      Australasia
      Central & South America
      Brazil
      Argentina
      Colombia
      Middle East & Africa
      Iran
      Israel
      Turkey
      South Africa
      Saudi Arabia

      Key manufacturers included in this survey
      Seres Therapeutics
      Second Genome
      Ritter Pharmaceuticals
      Rebiotix
      Pfizer
      OpenBiome
      MicroBiome Therapeutics
      MaaT Pharma
      Enterome Bioscience
      Buy now